Pictures
CAPE TOWN SLEDDING
ANIMAL ANTI-DOPING
ANTI-DOPING REGULATIONS
PREAMBLE:
The present WSA Anti-Doping Regulations are primarily intended to complement existing national anti-doping regulations and to define procedures
to be used specifically by the WSA.
In general, doping controls and disciplinary procedures will be carried out and administered under the existing national laws and by the National
Anti-Doping Organisations (NADO). If such laws or organisations do not exist at the time of the control and/or rules violation, or are not yet applied
by the WSA national member organisation, then the WSA anti-doping regulations and procedures below will apply.
Doping forms of a local laboratory are permitted if the major parts are translated into English.

GENERALITIES
9.1.1 Doping of humans
Concerning the use of prohibited substances by human athletes, the WSA adheres to the code of the World Anti-Doping Agency (WADA) and the
regulations, procedures and lists prescribed therein and applied as per the regulations of the national anti-doping organisations in the WSA
Member countries.
9.1.2 Doping of dogs
It is strictly forbidden, during competitions or other sports events organised or sanctioned under the WSA regulations, or during preparation for
participation therein:
? to use, administer or apply substances and procedures destined to artificially modify a dogs natural capacities or to
mask the use of substances or procedures having these properties;
? to have recourse to any substances or procedures whose use is subject to restrictive conditions, when these conditions are not respected
The substances and procedures referred to in 9.1.2. are those defined by the national anti-doping organisations, as well as those listed in 9.5 of
the present WSA regulations.
9.1.3 It is strictly forbidden, except under conditions prescribed in the national anti-doping regulations and in the WSA
regulations, to sell, offer or otherwise facilitate the use of subtances or procedures as defined in 9.1.2., or incite others to
use them.
9.1.4 It is forbidden to expressly avoid or otherwise oppose by any means doping control measures that have been officially
provided for at the national level or in the present WSA regulations, or to fail to comply with such measures without
compelling justification.
9.1.5 Violation of the anti-doping regulations will be dealt with in accordance with these rules and the WSA Penalty Provisions.

DOPING SUBSTANCES AND METHODS
9.2.1 Doping substances in dogs are, for the purpose of this rule, the substances defined by the national anti-doping
organisations and those listed in section 9.5 of the present regulations, as well as chemically and pharmacologically related compounds.
9.2.2 Blood doping
The practice of "Blood Doping" is, for the purpose of this rule, considered as use of a doping procedure.
9.2.3 Other methods
9.2.3.1 Other substances and methods are also considered as doping, for the purpose of this rule, if their
administration to dogs could have the same effect as mentioned in 9.1.2.1.
9.2.3.2 The following will not be considered as doping:
? Shaving a dog,
? Cooling down a heated dog with water and / or snow

DOPING CONTROL
Doping controls conducted as per the WSA Anti-Doping Regulations will be organised at WSA events whenever possible. In addition, doping
controls will be held if ordered by the WSA, or by the area or national race-giving organisation responsible for organising or sanctioning an event.

ANTI-DOPING COMMITTEE AT WSA-SANCTIONED EVENTS
9.2.3.2.1.1.1 Doping controls during competition will be carried out under the supervision of an Anti-Doping Committee for
the event. At international events, this committee must be composed of representatives from at least two
countries, and must be composed in such a way as to protect the interests of all concerned.
9.2.3.2.1.1.2 At WSA-sanctioned events, the Anti-Doping Committee will include:
9.2.3.2.1.1.2.1 The Chairperson of the anti-doping committee for the event, appointed by the WSA or the national anti-doping
organisation.
9.2.3.2.1.1.2.2 A member or representative of the WSA Veterinary Committee and/or the WSA Anti-Doping Committee,
designated by the WSA.
9.2.3.2.1.1.2.3 The approved doping control officers (DCO?s) designated to take the samples by the national anti-doping
organisation, or if this is not the case, by the WSA Board.
9.2.3.2.1.1.2.4 Additional qualified officers, when required by the national regulations applied by the race-giving organisation or
by the WSA.
9.4.3 At the request of the approved doping control officers the WSA may appoint delegates to assist the officers during
competitions or other sports events.
9.4.4 Members of the WSA Penal Committee may not be designated to participate in the anti-doping committees for events.

WSA LIST OF FORBIDDEN SUBSTANCES AND METHODS FOR DOGS.
9.2.3.2.1.1.3 No injectable, oral or topical drug or method which may suppress the signs of illness or injury may be
administered to a dog. No other drug or artificial means may be used to drive a dog or cause a dog to perform
or attempt to perform beyond its natural ability.
9.2.3.2.1.1.4 The following substances are prohibited:
9.2.3.2.1.1.4.1 Anabolic steroids
9.2.3.2.1.1.4.2 Analgesics (prescriptive and non-prescriptive)
9.2.3.2.1.1.4.3 Anaesthetics
9.2.3.2.1.1.4.4 Antihistamines
9.2.3.2.1.1.4.5 Anti-inflammatory drugs including but not limited to:
9.2.3.2.1.1.4.5.1 Cortico-steroids
9.2.3.2.1.1.4.5.2 Antiprostaglandins
9.2.3.2.1.1.4.5.3 Non-steroids
9.2.3.2.1.1.4.5.4 Salicylates
9.2.3.2.1.1.4.5.5 DSMO
9.2.3.2.1.1.4.6 Bronchiodilators
9.2.3.2.1.1.4.7 Central nervous system stimulants
9.2.3.2.1.1.4.8 Cough suppressants
9.2.3.2.1.1.4.9 Diuretics
9.2.3.2.1.1.4.10 Injectable anti-colenergics
9.2.3.2.1.1.4.11 Muscle relaxants
9.2.3.2.1.1.4.12 Sedatives and opiates
9.5.2.13 Alcohol
9.5.3 The use of nutrient shots is prohibited unless administered by an official race veterinarian during a given event.
9.5.4 Official race veterinarians may administer any of the prohibited substances and methods to a dog, after having withdrawn
the dog from the race. The use of local or general anesthetics may not be used in any form unless the dog is withdrawn
from the race.
9.5.5 Personal prescriptions issued to and carried by the competitor or his assistants, including products administered for estrus
suppression in intact bitches, may not be used unless they have the approval of an official race veterinarian.
9.5.6 In any case medical treatment of dogs at competitions is to be done strictly under the authorization of the official race
veterinarian, as per WSA regulations Part II, 1.1.3.

PROCEDURAL GUIDELINES FOR DOPING CONTROL
9.6.1 The procedural guidelines for the conduct of tests at WSA-sanctioned events, including the collection, recording and
shipping of samples for analysis, will be drawn up by the WSA Anti-Doping Committee in conformity with the
recommendations provided by the WADA Code. These guidelines will be published on the WSA Internet site with regular
updates as required. However, they will not supersede procedural guidelines and regulations established and
implemented by the national anti-doping organisations.
9.6.2 All officials concerned will acquaint themselves with the procedures. In particular, team officials will ensure that
competitors in their delegation have been informed in advance that they may be required to present dogs for doping
control and have understood the procedures that will be used.
9.6.3 Before the event, the criteria for selecting the competitors/dogs to be controlled will be determined by the Anti-Doping
Committee. This should either be on a final position basis and/or a random basis, but not by selection of named
individuals. Furthermore, the designated doping control officer will retain the possibility of controlling any dog at his
discretion.
9.6.4 Additional control may be ordered at the discretion of the Anti-Doping Committee or the race veterinarian.
9.6.5 A competitor will, if so requested in writing by the responsible official, submit his dog(s) to a doping control. Failure to do
so will result in immediate disqualification from the competition and the competitor will be subject to the disciplinary
procedures provided for in section 4.8 of these regulations. The same will apply if the competitor substitutes another dog
for any dog chosen for the test.
9.6.6 Only laboratories accredited or approved by the national anti-doping organisation or the WSA may be employed to carry
out analyses in connection with doping control.
9.6.7 Access to the laboratory during the analysis, if permitted, is restricted to members of the Anti-Doping Committee for the
event, the members of the WSA Veterinary and/or Anti-Doping Committee and to authorized observers.
9.6.7.1 No sample may be used for any purpose other than the detection of prohibited
9.6.7.2 Substances or methods on the doping lists referred to in the present regulations, or as may otherwise be publicly
announced by the ESDRA pursuant to an occasional monitoring program, without the written consent of the competitor or
the owner of the dog concerned.
9.7 COMMUNICATION OF RESULTS AND SUBSEQUENT PROCEDURES
9.7.1 The results of all analyses are to be communicated to the WSA Chairperson (Chief Executive Officer) and to the Head of
the WSA Anti-Doping Committee or his nominee in a report signed by an authorized representative of the laboratory or of
the national anti-doping organisation. The communication must be conducted in such a way that the results of the
analyses are confidential.
9.7.2 The evidence which has led to the indication of the presence of a prohibited substance must be made available.
9.7.3 If the analysis of the A sample indicates the presence of any prohibited substance(s), the WSA Chairperson will
immediately inform the competitor's national federation by registered receipt mail. The document will include the following
information:
9.7.3.1 A copy of the original doping control form signed by the doping control officer responsible for taking the samples and by
the competitor,
9.7.3.2 A copy of the official analysis report attesting to the presence of a prohibited substance or substances in the A sample,
9.7.3.3 The corresponding rules infraction(s),
9.7.3.4 The possibility of provisional suspension of the competitor as per section 4.8 of the present WSA regulations,
9.7.3.5 The competitor's right to provide his observations to the ESDRA Board, or to request a hearing with the WSA Sports,
Anti-Doping and Medical/Veterinary Committees, at cost to the competitor's national federation.
9.7.3.6 The competitor's right to request the analysis of the B sample, at cost to the competitor's national federation; and that,
failing such request, the B sample analysis may be deemed as waived. The request must be made by registered receipt
mail addressed to the WSA Chief Executive Officer within ten days after reception by the competitor's national federation
of the notification of the presence of prohibited substances in the A sample.
9.7.3.7 The competitor's right to request counter-expertise, at cost to the competitor's national federation, and to obtain a list of
approved laboratories. The request must be made by registered receipt mail addressed to the ESDRA Chief Executive
Officer within ten days after reception by the competitor's national federation of the notification of the presence of
prohibited substances in the A sample.
9.7.3.8 If permitted by the regulations applied by the laboratory chosen for the analysis of the B sample, the right of the
competitor or his representative to be present at the identification and opening of the B sample if an analysis of the B
sample is requested,
9.7.3.9 The right of the competitor to obtain copies of the analysis report of the B sample,
9.7.3.10 The competitor's right to admit to the rules violation and to signify this admission and consequently his decision to waive
the analysis of the B sample, by registered receipt mail addressed to the WSA Chief Executive Officer, within ten days
after reception by the competitor's national federation of the notification of the presence of prohibited substances in the A
sample,
9.7.3.11 That, in the event of the competitor's voluntary admission to the rules violation, the case will be immediately handed over
to the WSA Board for review and recommendations.
9.7.4 If the competitor requests the analysis of the B sample as per 4.7.3.6 the WSA will inform the competitor's national
federation of the date of the analysis which will be conducted as soon as possible by the laboratory that carried out the
analysis of the A sample. If permitted by the regulations applied by the laboratory, the WSA may at its discretion appoint a
neutral observer to be present, at cost to the competitor's national federation if the analysis of the B sample confirms the
analysis of the A sample.
9.7.5 If the competitor has requested a counter-expertise, he or his national federation will inform the WSA Board of the choice
of laboratory and the date of the B sample analysis. If permitted by the regulations applied by the laboratory chosen for
the counter-expertise, the WSA may at its discretion appoint a neutral observer to be present, at cost to the competitor's
national federation if the counter-expertise confirms the analysis of the A sample.
9.7.6 If the competitor has waived his right to the analysis of the B sample, be it by failure to make the request within the time
limit prescribed in paragraph 4.7.3.6, or by explicit indication of his decision to waive this right, the WSA Board may itself
request the analysis of the B sample if it so deems necessary. In this case the costs of the analysis of the B sample will
accrue to the WSA.
9.7.7 The results of the analysis of the B sample, or of the counter-expertise, will be sent to the ESDRA as per 4.7.1 and 4.7.2.
10. DISCIPLINARY ACTIONS.
10.1 Provisional suspension
10.1.1 In urgent situations, the WSA Board may immediately suspend the race results of a competitor concerned by a positive A
sample analysis consecutive to a doping control carried out on the competitor's dog(s) at an WSA-sanctioned event.
The WSA Board may impose such provisional suspension immediately upon the reception of a positive A sample analysis
result and before the opportunity for any hearing by the WSA Sports, Anti-Doping and Medical/Veterinary Committees or
any analysis of the B sample.
10.1.2 This provisional suspension may be extended to include that competitor's and/or dog(s)' participation in WSA-
sanctioned events scheduled after the date of reception of the results of the A sample analysis.
10.1.3 The competitor's federation will be informed of any provisional suspension without delay, by registered receipt mail.
10.1.4 If provisional suspension is imposed by the WSA Board, the competitor will be given an opportunity to provide his
observations to the WSA Chairperson within ten (10) days of reception of the notification by the national federation of the
provisional suspension, or to request, at cost to the competitor's national federation, a hearing by the WSA Sports, Anti-
Doping and Medical/Veterinary Committees on a timely basis after the imposition of the suspension.
10.1.5 If the result of the B sample analysis when carried out, or of the counter-expertise if requested by the competitor as per
4.7.3.7, is negative, any provisional suspension of the competitor's results and participation, if applied, will be canceled
upon reception by the WSA Chairperson of the results of the B sample analysis. The WSA will inform the competitor's
federation of this decision without delay.
10.1.6 If the analysis of the B sample, or of the counter-expertise, confirms the result of the analysis of the A sample, the WSA
will inform the competitor's federation as per section 4.7.3 of these regulations that he has contravened the WSA Anti-
Doping Regulations and has been disqualified from the competition at which his dog's positive A sample was taken. The
case will then be decided on by the WSA Board.
10.1.7 If provisional extension has been extended as per 4.8.1.2, the WSA Board may decide to maintain said suspension. The
WSA will inform the competitor's federation of this decision without delay, by registered receipt mail.
10.1.8 If provisional suspension from participation in WSA events as per paragraph 4.8.1.2 has not been applied, the WSA
Board may at this time decide to impose such a suspension. The WSA will inform the competitor's federation of this
decision without delay, by registered receipt mail.
10.2 Disciplinary actions
10.2.1 Sports penalties: disqualification
10.2.2 Disciplinary measures chosen from the following:
a. warning
b. suspension or definitive exclusion from participation in WSA sanctioned events
c. suspension or definitive exclusion from direct or indirect participation in the organisation and implementation of WSA sanctioned events
d. suspension or definitive exclusion from officiating as an WSA-licensed race official or an WSA administrator
e. suspension or definitive exclusion from participation in the WSA Congress
f. expulsion
10.2.3 If the WSA Board decides on a suspension from participation in WSA-sanctioned events as per (b) above, the duration of
any provisional suspension already fulfilled by the competitor shall be taken into consideration.
10.2.4 The WSA Board set the date at which the disciplinary action will come into force. Disciplinary measures of less than six
(6) months' duration may not be fulfilled outside the period of competition.
10.2.5 If, upon reception of the results of the A analysis, with subsequent confirmation by the B analysis if carried out, the WSA
Board considers that the offender has misunderstood the present doping control regulations, the maximum duration of the
disciplinary measures provided for in (b-e) of paragraph 4.8.2.2 will be three years. If a second offense for doping occurs
within five years of the date of the first offense, the offender will be permanently expelled.
10.2.6 In the case of a first offense as per the present doping control regulations, the maximum duration of the disciplinary
measures provided for in b-e of ? 4.8.2.2 will be five years. If a second offense for doping occurs, the offender will be
permanently expelled.
10.3 Right of Appeal
10.3.1 The offender will have the right to appeal the disciplinary actions imposed upon him to the WSA Board, as the first
appeals instance, and to the WSA G.A.at the second appeals instance.
10.3.2 Within thirty (30) days after reception by the competitor's national federation of the notification of the disciplinary action(s)
imposed upon the competitor, the latter may address a first appeal to the WSA Board. The appeal must be sent by
registered receipt mail, in English, to the WSA Chairperson and must include the competitor's arguments and
justifications.
10.3.3 The WSA Board will examine the appeal in a timely manner and inform the competitor and his federation of its decision by
registered receipt mail.
10.3.4 In exceptional cases, the competitor or the WSA Board may request a hearing to examine the appeal. In this case:
? The competitor may be accompanied by his legal representative,
? The WSA may invite the Sports director, and/or the Chairperson of the Anti-Doping Committee, and/or the WSA
Chief Veterinarian of the event the doping occurred at, as deemed necessary, to participate in the hearing,
? The date and place of the hearing will be set at the earliest possible convenience of all parties,
? If the hearing is to be held at the request of the competitor, the costs will be borne by the competitor's national
federation.
10.3.5 Within thirty (30) days after reception of the WSA Board's decision in a first appeal, the competitor may address a second
appeal to the WSA G.A.. The appeal must be sent by registered receipt mail, in English, to the WSA Chairperson and

appeal must include the competitor's arguments and justifications.
The appeal will be handled at the following WSA Congress of Delegates (G.A.). However, if the time frame until the
Congress is unreasonably long, the Members may be consulted and render their decision by mail vote if provided for in
the WSA Statutes and Administrative Regulations 1.2.11.6.
10.3.5 The Court of Arbitration for Sport will be the final appeals instance in all cases. Any costs arising from calling the Court of
Arbitration will be born by the defendant independent of the outcome or court decision.
11. Final Dispositions
11.1 The competitor's national federation should carry out an investigation to ascertain:
? the source of the illegal substances,
? any earlier use of illegal substances or illegal methods,
? the identity of any persons inciting the competitor to use illegal drugs or employ illegal methods.
A report of all findings will be made to the WSA.
The competitor's national federation will implement the WSA penalties also for it's area of juristriction and sanctioned events.
11.2 Any offences under this rule arising from events held at a national level will be reported to the WSA by the national
federation. The WSA Board may then decide to consult the WSA Board on further disciplinary action.

ANNEXURE "A"

The World Anti-Doping Code
THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict
between the English and French versions, the English version shall prevail.

This List shall come into effect on 1 January 2008
The Prohibited List 2008
September 22, 2007
THE 2008 PROHIBITED LIST
WORLD ANTI-DOPING CODE
Valid 1 January 2008

The use of any drug should be limited to medically justified indications

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)
PROHIBITED SUBSTANCES

S1. ANABOLIC AGENTS
Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS, including:
1-androstendiol (5?-androst-1-ene-3?,17?-diol );
1-androstendione (5?-androst-1-ene-3,17-dione);
bolandiol (19-norandrostenediol);
bolasterone;
boldenone;
boldione (androsta-1,4-diene-3,17-dione);
calusterone;
lostebol;
danazol (17?-ethynyl-17?-hydroxyandrost-4-eno[2,3-d]isoxazole);
dehydrochlormethyltestosterone(4-chloro-17?-hydroxy-17?-methylandrosta-1,4-dien-3-one);
desoxymethyltestosterone (17?-methyl-5?-androst-2-en-17?-ol);
drostanolone; ethylestrenol (19-nor-17?-pregn-4-en-17-ol);
fluoxymesterone;
formebolone;
furazabol (17?-hydroxy-17?-methyl-5?-androstano[2,3-c]-furazan);
gestrinone;
4-hydroxytestosterone(4,17?-dihydroxyandrost-4-en-3-one);
mestanolone;
mesterolone;
metenolone;
methandienone (17?-hydroxy-17?-methylandrosta-1,4-dien-3-one);
methandriol;
methasterone (2?, 17?-dimethyl-5?-androstane-3-one-17?-ol);
methyldienolone (17?-hydroxy-17?-methylestra-4,9-dien-3-one);
methyl-1-testosterone (17?-hydroxy-17?-methyl-5?-androst-1-en-3-one);
methylnortestosterone (17?-hydroxy-17?-methylestr-4-en-3-one);
methyldienolone (17?-hydroxy-17?-methylestra-4,9,11-trien-3-one);
methyl testosterone;
mibolerone;
nandrolone;
19-norandrostenedione (estr-4-ene-3,17-dione);
norboletone;
norclostebol;
norethandrolone;
oxabolone;
oxandrolone;
oxymesterone;
oxymetholone;
prostanozol ([3,2-c]pyrazole-5?-etioallocholane-17?-tetrahydropyranol);
quinbolone;
stanozolol;
stenbolone;
1-testosterone (17?-hydroxy-5?-androst-1-en-3-one);
tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17?-ol-3-one);

The Prohibited List 2008
September 22, 2007
2
Trenbolone and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous** AAS:
Androstenediol (androst-5-ene-3?,17?-diol);
androstenedione (androst-4-ene-3,17-dione);
dihydrotestosterone (17?-hydroxy-5?-androstan-3-one) ;
prasterone (dehydroepiandrosterone, DHEA);
testosterone

And the following metabolites and isomers:
5?-androstane-3?,17?-diol;
5?-androstane-3?,17?-diol;
5?-androstane-3?,17?-diol;
5?-androstane-3?,17?-diol;
androst-4-ene-3?,17?-diol;
androst-4-ene-3?,17?-diol;
androst-4-ene-3?,17?-diol;
androst-5-ene-3?,17?-diol;
androst-5-ene-3?,17?-diol;
androst-5-ene-3?,17?-diol;
4-androstenediol (androst-4-ene-3?,17?-diol);
5-androstenedione (androst-5-ene-3,17-dione);
epi-dihydrotestosterone;
3?-hydroxy-5?-androstan-17-one;
3?-hydroxy-5?-androstan-17-one;
19-norandrosterone;
19-noretiocholanolone.

Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance
and an Adverse Analytical Finding will be reported where the concentration of such Prohibited Substance or its metabolites or markers and/or any
other relevant ratio(s) in the Athlete's Sample so deviates from the range of values normally found in humans that it is unlikely to be consistent with
normal endogenous production. A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that
the concentration of the Prohibited Substance or its metabolites or markers and/or the relevant ratio(s) in the Athlete's Sample is attributable to a
physiological or pathological condition.

In all cases, and at any concentration, the Athlete's Sample will be deemed to contain a Prohibited Substance and the laboratory will report an
Adverse Analytical Finding if, based on any reliable analytical method (e.g. IRMS), the laboratory can show that the

Prohibited Substance is of exogenous origin. In such case, no further investigation is necessary.

When a value does not so deviate from the range of values normally found in humans and any reliable analytical method (e.g. IRMS) has not
determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of
a possible Use of a Prohibited Substance, or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and any reliable analytical
method (e.g. IRMS) has not determined the exogenous origin of the substance, further investigation shall be conducted by the relevant Anti-Doping
Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s).

When such further investigation is required the result shall be reported by the laboratory as atypical and not as adverse. If a laboratory reports,
using an The Prohibited List 2008 September 22, 2007

3
additional reliable analytical method (e.g. IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary, and the
Sample will be deemed to contain such Prohibited Substance. When an additional reliable analytical method (e.g. IRMS) has not been applied, and
the minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing three
no-advance notice tests in a period of three months by the relevant Anti-Doping Organization. The result that triggered this longitudinal study shall
be reported as atypical. If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically normal, the result shall
then be reported as an Adverse Analytical Finding.

In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per millilitre (ng/mL) levels in
urine. When such a very low concentration of boldenone is reported by a laboratory and the application of any reliable analytical method (e.g.
IRMS) has not determined the exogenous origin of the substance, further investigation may be conducted by subsequent test(s).

For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin
of the Prohibited Substance. In such case, no further investigation is necessary.
Should an Athlete fail to cooperate in the investigations, the Athlete's Sample shall be deemed to contain a Prohibited Substance.

2. Other Anabolic Agents, including but not limited to:
Clenbuterol,
selective androgen receptor modulators (SARMs),
tibolone,
zeranol,
zilpaterol.

For purposes of this section:
* "exogenous" refers to a substance which is not ordinarily capable of being produced by the body naturally.
** "endogenous" refers to a substance which is capable of being produced by the body naturally.

S2. HORMONES AND RELATED SUBSTANCES
The following substances and their releasing factors are prohibited:

1. Erythropoietin (EPO);
2. Growth Hormone (hGH), Insulin-like Growth Factors (e.g. IGF-1), Mechano Growth Factors (MGFs);
3. Gonadotrophins (e.g. LH, hCG), prohibited in males only;
4. Insulins;
5. Corticotrophins.
The Prohibited List 2008
September 22, 2007
4
And other substances with similar chemical structure or similar biological effect(s).
Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain
a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers
in the Athlete's Sample so exceeds the range of values normally found in humans that it is unlikely to be consistent with normal endogenous
production.
If a laboratory reports, using a reliable analytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to
contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding.
S3. BETA-2 AGONISTS
All beta-2 agonists including their D- and L-isomers are prohibited.
As an exception, formoterol, salbutamol, salmeterol and terbutaline when administered by inhalation, require an abbreviated Therapeutic Use
Exemption.
Despite the granting of any form of Therapeutic Use Exemption, a concentration of salbutamol (free plus glucuronide) greater than 1000 ng/mL will
be considered an Adverse Analytical Finding unless the Athlete proves that the abnormal result was the consequence of the therapeutic use of
inhaled salbutamol.
S4. HORMONE ANTAGONISTS AND MODULATORS
The following classes are prohibited:
1. Aromatase inhibitors including, but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane, formestane, testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.
4. Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors.
The Prohibited List 2008
September 22, 2007
5
S5. DIURETICS AND OTHER MASKING AGENTS
Masking agents are prohibited. They include:
Diuretics*, epitestosterone, probenecid, alpha-reductase inhibitors (e.g. finasteride, dutasteride), plasma expanders (e.g. albumin, dextran,
hydroxyethyl starch) and other substances with similar biological effect(s).
Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides
(e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar
biological effect(s) (except for drosperinone, which is not prohibited).
* A Therapeutic Use Exemption is not valid if an Athlete's urine contains a diuretic in association with threshold or sub-threshold levels of a
Prohibited Substance(s).
The Prohibited List 2008
September 22, 2007
6
PROHIBITED METHODS
M1. ENHANCEMENT OF OXYGEN TRANSFER
The following are prohibited:
1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and
modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products).
M2. CHEMICAL AND PHYSICAL MANIPULATION
1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. These
include but are not limited to catheterisation, urine substitution and/or alteration.
2. Intravenous infusion is prohibited. In an acute medical situation where this method is deemed necessary, a retroactive Therapeutic Use
Exemption will be required.
M3. GENE DOPING
The non-therapeutic use of cells, genes, genetic elements, or of the modulation of gene expression, having the capacity to enhance athletic
performance, is prohibited.
The Prohibited List 2008
September 22, 2007
7
SUBSTANCES AND METHODS
PROHIBITED IN-COMPETITION
In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:
PROHIBITED SUBSTANCES
S6. STIMULANTS
All stimulants (including both their (D- & L-) optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those
stimulants included in the 2008 Monitoring Program*.
Stimulants include:
Adrafinil, adrenaline**, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine***,
clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine****, etamivan, etilamphetamine, etilefrine,
famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene,
levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine,
methylenedioxymethamphetamine, p-methylamphetamine, methylephedrine****, methylphenidate, modafinil, nikethamide, norfenefrine,
norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine,
phenpromethamine, phentermine, 4-phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine, tuaminoheptane
and other substances with a similar chemical structure or similar biological effect(s).
* The following substances included in the 2008 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol,
pseudoephedrine, synephrine) are not considered as Prohibited Substances.
** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited.
*** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per millilitre.
**** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per millilitre.
The Prohibited List 2008
September 22, 2007
8
A stimulant not expressly mentioned as an example under this section should be considered as a Specified Substance only if the Athlete can
establish that the substance is particularly susceptible to unintentional anti-doping rule violations because of its general availability in medicinal
products or is less likely to be successfully abused as a doping agent.
S7. NARCOTICS
The following narcotics are prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone,
oxymorphone, pentazocine, pethidine.
S8. CANNABINOIDS
Cannabinoids (e.g. hashish, marijuana) are prohibited.
S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered orally, rectally, intravenously or intramuscularly. Their use requires a Therapeutic Use
Exemption approval.
Other routes of administration (intraarticular /periarticular/ peritendinous/ epidural/ intradermal injections and inhalation) require an Abbreviated
Therapeutic Use Exemption except as noted below.
Topical preparations when used for dermatological (including iontophoresis/phonophoresis), auricular, nasal, ophthalmic, buccal, gingival and
perianal disorders are not prohibited and do not require any form of Therapeutic Use Exemption.
The Prohibited List 2008
September 22, 2007
9
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
P1. ALCOHOL
Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The
doping violation threshold (haematological values) for each Federation is reported in parenthesis.
? Aeronautic (FAI) (0.20 g/L)
? Archery (FITA, IPC) (0.10 g/L)
? Automobile (FIA) (0.10 g/L)
? Boules (IPC bowls) (0.10 g/L)
? Karate (WKF) (0.10 g/L)
? Modern Pentathlon (UIPM) (0.10 g/L) for disciplines involving shooting
? Motorcycling (FIM) (0.10 g/L)
? Powerboating (UIM) (0.30 g/L)
P2. BETA-BLOCKERS
Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports.
? Aeronautic (FAI)
? Archery (FITA, IPC) (also prohibited Out-of-Competition)
? Automobile (FIA)
? Billiards (WCBS)
? Bobsleigh (FIBT)
? Boules (CMSB, IPC bowls)
? Bridge (FMB)
? Curling (WCF)
? Gymnastics (FIG)
? Motorcycling (FIM)
? Modern Pentathlon (UIPM) for disciplines involving shooting
? Nine-pin bowling (FIQ)
? Powerboating (UIM)
? Sailing (ISAF) for match event helms only
? Shooting (ISSF, IPC) (also prohibited Out-of-Competition)
? Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
? Wrestling (FILA)
Beta-blockers include, but are not limited to, the following:
Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol,
nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. The Prohibited List 2008
September 22, 2007
10
SPECIFIED SUBSTANCES*
?Specified Substances?* are listed below:
? All inhaled Beta-2 Agonists, except salbutamol (free plus glucuronide) greater than 1000 ng/mL and clenbuterol (listed under S1.2: Other
Anabolic Agents);
? Alpha-reductase inhibitors, probenecid;
? Cathine, cropropamide, crotetamide, ephedrine, etamivan, famprofazone, heptaminol, isometheptene, levmethamfetamine, meclofenoxate,
p-methylamphetamine, methylephedrine, nikethamide, norfenefrine, octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine,
selegiline, sibutramine, tuaminoheptane, and any other stimulant not expressly listed under section S6 for which the Athlete establishes that it
fulfils the conditions described in section S6;
? Cannabinoids;
? All Glucocorticosteroids;
? Alcohol;
? All Beta Blockers.
* ?The Prohibited List may identify specified substances which are particularly susceptible to unintentional anti-doping rule violations because of
their general availability in medicinal products or which are less likely to be successfully abused as doping agents.? A doping violation involving
such substances may result in a reduced sanction provided that the ??Athlete can establish that the Use of such a specified substance was not
intended to enhance sport performance??
The Prohibited List 2008 11
September 22, 2007